USVM's Underlying Holdings Imply 13% Gain Potential

The VictoryShares US Small Mid Cap Value Momentum ETF (USVM) exhibits a 13.10% implied upside to an average analyst 12-month target price of $102.75, based on the weighted average of its underlying holdings' analyst targets. Several key components, including Cidara Therapeutics (CDTX), Gulfport Energy (GPOR), and Ziff Davis (ZD), show significant individual upside potential of 37.04%, 18.57%, and 18.27% respectively. This analysis suggests notable analyst optimism for the ETF's constituent companies, prompting investors to further evaluate the justification of these price targets.

Analysis

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the VictoryShares US Small Mid Cap Value Momentum ETF (Symbol: USVM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $102.75 per unit. With USVM trading at a recent price near $90.85 per unit, that means that analysts see 13.10% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of USVM's underlying holdings with notable upside to their analyst target prices are Cidara Therapeutics Inc (Symbol: CDTX), Gulfport Energy Corp. (Symbol: GPOR), and Ziff Davis Inc (Symbol: ZD). Although CDTX has traded at a recent price of $98.51/share, the average analyst target is 37.04% higher at $135.00/share. Similarly, GPOR has 18.57% upside from the recent share price of $187.76 if the average analyst target price of $222.64/share is reached, and analysts on average are expecting ZD to reach a target price of $45.28/share, which is 18.27% above the recent price of $38.29. Below is a twelve month price history chart comparing the stock performance of CDTX, GPOR, and ZD: Below is a summary table of the current analyst target prices discussed above: | Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target | |---|---|---|---|---| | VictoryShares US Small Mid Cap Value Momentum ETF | USVM | $90.85 | $102.75 | 13.10% | | Cidara Therapeutics Inc | CDTX | $98.51 | $135.00 | 37.04% | | Gulfport Energy Corp. | GPOR | $187.76 | $222.64 | 18.57% | | Ziff Davis Inc | ZD | $38.29 | $45.28 | 18.27% | Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Do the analysts have a valid justification for their targets, or are they behind the curve on recent company and industry developments? A high price target relative to a stock's trading price can reflect optimism about the future, but can also be a precursor to target price downgrades if the targets were a relic of the past. These are questions that require further investor research. 10 ETFs With Most Upside To Analyst Targets » Also see: Institutional Holders of DTJ Ameren shares outstanding history MEC market cap history The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The VictoryShares US Small Mid Cap Value Momentum ETF (USVM) currently presents an implied 13.10% upside, projecting a move from its recent price of $90.85 to an average analyst 12-month target of $102.75 per unit. This optimistic outlook is derived from the weighted average of analyst target prices for its underlying holdings. The general sentiment surrounding this ETF, as indicated by the analysis, is mildly positive, aligning with the potential for capital appreciation. Key individual components significantly contributing to USVM's implied upside include Cidara Therapeutics Inc (CDTX), Gulfport Energy Corp. (GPOR), and Ziff Davis Inc (ZD). CDTX exhibits the highest individual implied upside at 37.04% from its recent price of $98.51 to a $135.00 target. GPOR and ZD also show substantial potential, with implied upsides of 18.57% and 18.27% respectively, reflecting specific analyst confidence in these companies. However, the analysis explicitly raises questions regarding the justification and recency of these analyst targets. It cautions that such targets, while reflecting optimism, might be a relic of past conditions and could be susceptible to downgrades if not aligned with current company and industry developments. This introduces a critical caveat, emphasizing the need for further investor scrutiny beyond the headline upside figures.

Key Decisions for Investors

• Investors should conduct independent due diligence on USVM's key underlying holdings, especially Cidara Therapeutics (CDTX), Gulfport Energy (GPOR), and Ziff Davis (ZD), to validate the currency and fundamental support for the implied analyst target prices.
• Monitor company-specific news and industry trends for the ETF's constituents, as outdated analyst targets may not fully reflect recent developments and could lead to future target price revisions.
• Consider the USVM ETF as a potential value opportunity based on the aggregate analyst consensus, but acknowledge the inherent risk that the implied upside is heavily reliant on potentially optimistic or unverified analyst expectations.